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Strengths and limitations of this study
 ► Our systematic review and random-effects network 
meta-analysis (NMA) will provide pragmatic answers 
to a critical question in the field of psychiatry: which 
drug or drugs combination, if any, is currently the 
best evidence-based choice in terms of efficacy and 
tolerability for rapid tranquillisation of aggression or 
agitation episodes in individuals with psychosis?
 ► The analysis will benefit from maximum statistical 
power by combining direct and indirect comparisons 
in an NMA, measuring the relative efficacy of these 
treatments.
 ► We will evaluate the contribution of drugs to their 
combination intervention by performing a compo-
nent NMA as a sensitivity analysis.
 ► Limitations of individual studies will be judged with 
the revised Cochrane risk of bias tool (RoB 2) and the 
credibility of the results for the main outcomes will 
be assessed using the Confidencein Network Meta-
Analysis web application.
 ► Some studies might have evaluated more pragmatic 
outcomes without a continuous measurement of the 
level of aggression or agitation, thus not being able 
to contribute our primary efficacy outcome.
AbStrACt
Introduction Individuals with psychosis may access 
emergency services due to aggression and agitation. 
When the de-escalation technique fails to achieve 
tranquillisation, several pharmacological options are 
available. However, evidence on which intervention to 
prefer in terms of efficacy and tolerability to achieve 
resolution of the acute episode (ie, rapid tranquillisation) of 
aggression and agitation is currently fragmentary.
Methods and analysis We will include all randomised 
controlled trials comparing drugs or drug combinations 
or placebo for aggression or agitation episodes in adult 
individuals with psychosis. We will include individuals 
with psychosis (eg, schizophrenia and related disorders, 
bipolar disorder with psychotic symptoms, psychotic 
depression) but not substance or medication-induced 
psychosis or psychosis due to another medical condition. 
Our primary outcomes are the change in aggression or 
agitation scores within few hours since the administration 
of the intervention (efficacy outcome) and the proportion 
of participants who dropped out due to adverse effects 
(tolerability outcome). We will retrieve relevant studies 
from the register of studies of the Cochrane Schizophrenia 
Group. Also, we will run additional searches on CENTRAL, 
Embase and PubMed to retrieve potentially eligible studies 
focusing on other psychiatric diagnoses than those in the 
schizophrenia spectrum. We will conduct a random-effects 
network meta-analysis (NMA) for primary and secondary 
outcomes. In case of rare events of dichotomous 
outcomes, a common-effect Mantel-Haenszel NMA will be 
used instead. We will use the surface under the cumulative 
ranking curve and the mean ranks to rank all available 
treatments. Local and global methods of evaluation of 
inconsistency will be employed. Quality of evidence 
contributing to network estimates of the main outcomes 
will also be assessed with Confidence in Network Meta-
Analysis.
Ethics and dissemination This study does not require 
ethical approval. We will disseminate our findings by 
publishing results in a peer-reviewed journal.
PrOSPErO registration number CRD42019137945.
bACkgrOund
Mental health-related behavioural emer-
gencies are reported to account for around 
6% of the visits to the emergency depart-
ment in USA.1 In this context, aggression 
and agitation are clinically relevant issues in 
both psychiatric and emergency department 
settings.2 Verbal and physical aggression may 
result from psychomotor agitation, of which 
restlessness, excitability and dysphoria are 
prominent symptoms.3 4 Violent behaviour 
has been reported to occur in 18.5% of partic-
ipants with psychosis included in a recently 
published systematic review.5 Consequences 
of this phenomenon may affect patients, their 
caregivers, healthcare personnel and commu-
nity members, both in terms of harmful events 
towards self or others and stigma-driven victi-
misation of patients.6–9
copyright.
 o
n
 N
ovem
ber 4, 2019 at University of Nottingham
. Protected by
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2019-032726 on 10 October 2019. Downloaded from 
2 Ostinelli EG, et al. BMJ Open 2019;9:e032726. doi:10.1136/bmjopen-2019-032726
Open access 
When facing acutely aggressive and agitated individ-
uals, guidelines recommends clinicians to assess the 
feasibility of management with de-escalation techniques. 
Should this be deemed unpractical or proven ineffective, 
a pharmacological approach is the mainstay for rapid 
tranquillisation.10 11 Several systematic reviews have eval-
uated the comparative efficacy and safety of pharmaco-
logical interventions from randomised controlled trials 
(RCTs) in schizophrenia spectrum illness.12–24 These 
reviews contributed currently available policy-making 
policies: for instance, NICE guidelines recommend the 
use of lorazepam or the combination of haloperidol 
and promethazine as pharmacological interventions for 
aggression and agitation in the context of schizophrenia 
spectrum illnesses.11
However, evidence supporting these recommenda-
tions is still fragmentary and a comprehensive ranking 
of all treatments evaluated in RCTs is still lacking. Also, 
several interventions lack of head-to-head comparisons 
with recommended and available treatment options. 
For example, none of the identified RCTs compared the 
intramuscular administration of the second-generation 
antipsychotic aripiprazole with either lorazepam or the 
haloperidol and promethazine combination.11 20
Network meta-analysis (NMA) is a statistical technique 
that provides estimates through direct and indirect 
comparisons and allows to assess the relative ranking of 
different treatments, ultimately resulting in increased 
precision.25 Objective of this systematic review and NMA 
is to compare available pharmacological interventions in 
terms of efficacy and tolerability in the acute treatment of 
aggression and agitation episode (ie, rapid tranquillisa-
tion) in adults with psychosis presenting to an acute care 
setting. In order to ensure our findings to be pragmatic 
and to provide clinically meaningful recommendations, 
we will focus on the transdiagnostic concept of psychosis 
when not induced by substance or medication use or 
other medical conditions.
MEthOdS
We submitted this study protocol to PROSPERO 
(CRD42019137945). Methods for this systematic review 
and NMA have been developed following the Preferred 
Reporting Items for Systematic Review and Meta-Analysis 
(PRISMA) guideline for systematic review and meta-anal-
ysis protocols (PRISMA-P, online supplementary file 1), 
the extension statement for NMA (PRISMA-NMA, online 
supplementary file 2) and proposed additional consid-
erations for protocols of systematic reviews including 
NMA.26–29
Criteria for considering studies for this review
Types of studies
RCTs reported as double-blind will be included. Single-
blind and open studies will be included but the effect 
of their inclusion will be evaluated in a sensitivity anal-
ysis. Quasi-randomised studies (eg, allocating by using 
alternate days of the week) will be excluded. Cross-over 
and cluster randomised trials will be included. Studies 
where sequence generation was at high risk of bias or 
where allocation was clearly not concealed will not be 
included.
Types of participants
Individuals aged 18 years or older, of both sexes, showing 
psychotic symptoms and an aggression or agitation 
episode deemed to be in need of pharmacological tran-
quillisation. We will also include studies in which base-
line mean scores of an aggression or agitation rating 
scale suggest the need of pharmacological tranquillisa-
tion (eg, Positive and Negative Syndrome Scale Excited 
Component (PANSS-EC)≥14, Modified Overt Aggression 
Scale (MOAS)≥4). The impact of including these studies 
will be analysed (refer to the Exploring heterogeneity, 
inconsistency and sensitivity analyses section). Studies 
will be considered eligible only if psychotic symptoms 
are thought to be secondary to an established psychi-
atric diagnosis (eg, schizophrenia, schizophreniform 
disorder, schizoaffective disorder, delusional disorder, 
brief psychotic disorder, bipolar mania or depression 
with psychotic features, psychotic depression) in at least 
50% of the randomised population. Psychotic disorders 
induced by substances or medications or due to another 
medical condition (eg, dementia, Parkinson’s disease, 
autoimmune disorders, neurodevelopmental disorders) 
will not be considered eligible. Peri-partum psychosis will 
not be considered eligible. A concurrent secondary diag-
nosis of another psychiatric disorder will not be consid-
ered as exclusion criteria. Treatment settings may be the 
outpatient emergency departments or the hospital wards.
Types of interventions
We aim to synthesise available data for first-generation 
antipsychotics, second-generation antipsychotics, benzo-
diazepines, antihistaminic drugs and valproic acid or 
their combinations. We will obtain information about the 
interventions of interest from head-to-head and place-
bo-controlled trials (ie, pill or pharmacological placebo). 
Inclusion of placebo-controlled trials may contribute 
via indirect evidence to the treatment comparisons of 
interest by increasing the precision and allowing addi-
tional connections in the network. Pharmacological 
interventions not described above will be considered for 
post-hoc inclusion in the network within the context of 
the joint randomisability assumption by evaluation of 
their effect as rapid tranquilliser. Interventions (drugs or 
drug combinations) may be administered via any route 
of administration consistent with the rapid tranquillisa-
tion aim (ie, long-acting injectable antipsychotics are not 
eligible since they aim at maintenance treatment). Any 
dosing strategy (ie, flexible or fixed) will be allowed. We 
will allow multiple administrations and we will consider 
them when evaluating the eligibility of dosages and fair-
ness of comparisons for the primary efficacy outcome. 
Multiple administrations, when not delivered following a 
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fixed schedule, will contribute to the ‘individuals needing 
additional interventions’ outcome. We will include only 
study arms in which individuals have been randomised 
to drugs within the recommended dose range for aggres-
sive or agitated individuals with psychosis.30 Should these 
not be available in the current literature, we will consider 
licensed dose ranges for psychiatric or, if absent, medical 
conditions. If a study included arms with both approved 
and unapproved doses, we will include only those arms 
that employed eligible doses. Should a comparison 
include different dosages of the same drug, we will 
consider them as a single node as long as the dosages are 
within the eligible range. Therefore, studies comparing 
the same drug at different dosages without another inter-
vention will not contribute the network. For studies with a 
fixed dosing strategy, we will consider the planned dosage 
as the administered one. If a study employs a flexible 
dosing strategy, we will abide by the following hierarchy: 
(1) mean dose within 48 hours since the first administra-
tion; (2) mean dose until the end of the study; (3) average 
between the minimum and maximum doses allowed. 
Fairness of dose comparisons in head-to-head trials will 
be evaluated in a sensitivity analysis. Drug monotherapies 
and drug combinations within eligible dose ranges will be 
treated initially as different nodes in the network.
Outcome measures
Our primary outcomes are:
1. Efficacy (as continuous outcome)—aggression or ag-
itation scores as close to 2 hours as possible since ad-
ministration of the intervention (range:>0,≤6 hours). 
Endpoint scores will be preferred to change scores, 
if both are reported. We will employ validated rat-
ing scales or subscales commonly used to evaluate 
aggression or agitation including but not limited to 
Behavioral Activity Rating Scale,31 Corrigan Agitated 
Behavior Scale,32 Overt Agitation Severity Scale,33 
MOAS34 35 or PANSS-EC.36 If more than one scale has 
been administered, we will prioritise scales measuring 
aggression over agitation and scales over subscales. 
It is likely that across included trials different rating 
scales have been used to measure the same outcome.37 
To overcome this, we plan to harmonise continuous 
outcomes to a common metric (ie, standardised mean 
difference (SMD)). We acknowledge that during a trial 
additional drugs may be administered as rescue drug 
to give relief from adverse events. Should this occur, we 
will use the closest time point to 2 hours after baseline 
at which additional drugs have not yet been adminis-
tered. Should this be unavailable, we will include data 
only if administration of rescue drugs was not unbal-
anced between the groups (eg, mean value of daily ad-
ministered milligrams) and we will evaluate the impact 
of their inclusion in a sensitivity analysis (refer to the 
Exploring heterogeneity, inconsistency and sensitivi-
ty analyses section). If both aggression and agitation 
data are collected within the same trial at the preferred 
time points, we will choose the aggression one since it 
is more representative of clinical urgency. If only agi-
tation outcomes have been measured or reported, we 
will use this as a proxy of aggression outcome.
2. Tolerability (as dichotomous outcome)—dropouts due 
to adverse events as close as to 24 hours since the ad-
ministration of the intervention (range: >0, ≤7 days).
Our secondary outcomes include:
1. Efficacy (as continuous outcome)—aggression or 
agitation scores as close to 24 hours as possible since 
the administration of the intervention (range: >6, 
≤48 hours).
2. Efficacy (as dichotomous outcome)—proportion of 
individuals needing one or more additional interven-
tions (ie, additional administration of any drugs to 
achieve tranquillisation, needing restraints or seclu-
sion) up to 6 hours since the administration of the in-
tervention (range: >0, ≤6 hours). When the number of 
individuals in need of additional treatment is reported 
specifically for every adjunctive care option, summing 
these data may lead to double counting issues (ie, in-
dividuals who needed two or more different additional 
interventions). Hence, we will abide by the following 
order: (1) additional administration of any drugs, (2) 
needing restraints and (3) needing seclusion.
3. Efficacy (as dichotomous outcome)—proportion of 
individuals needing an additional intervention (ie, ad-
ditional administration of any drugs to achieve tran-
quillisation, needing restraints or seclusion) up to 
48 hours since the administration of the intervention 
(range: >0, ≤48 hours). Outcomes will be prioritised as 
stated above.
4. Tolerability (as dichotomous outcome)—proportion 
of individuals with at least one serious side effect as 
close to 24 hours as possible since the administration 
of the intervention (range: >0, ≤7 days). We define ‘se-
rious’ side effects as stated by the original investigators.
For the efficacy outcomes, should two available meas-
urements be equidistant from the predefined time point 
we will prioritise earlier time points within the above 
stated range. For the tolerability outcomes, should the 
same conditions apply we will prefer later estimates over 
the earlier if both are eligible.
Search strategy
We will search the Cochrane Schizophrenia Group 
register for studies relevant to aggression and agitation 
in schizophrenia spectrum illnesses. In this study-based 
register, searching the major concept retrieves all the 
synonyms and relevant studies because all the studies 
have already been organised based on their interven-
tions and linked to the relevant topics. This allows rapid 
and accurate searches that reduce waste in the next steps 
of systematic reviewing.38 39 This register is compiled 
by systematic searches of major resources (AMED, 
1985–present; BIOSIS, 1969–present; CENTRAL, not 
applicable; CINAHL, 1982–present; ClinicalTrials.
Gov, 2000–present; Embase, 1974–present; ISRCTN, 
2000–present; MEDLINE, 1946–present; PsycINFO, 
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1806–present; PubMed, 1946–present; WHO ICTRP, 
2000–present) and their monthly updates, ProQuest 
Dissertations and Theses A&I (1637–present) and its 
quarterly update, Chinese databases (CNKI, 1994–
present; SinoMed, 1978–present; VIP, 1989–present; 
Wanfang, unclear–present) and their annual updates, 
hand-searches, grey literature and conference proceed-
ings.40 There is no language, date, document type, or 
publication status limitations for inclusion of records 
into the register. An additional search on CENTRAL (not 
applicable), Embase (1974-present) and PubMed (1946-
present) databases will be performed with keywords rele-
vant to psychotic depression, episodes of bipolar mania 
or depression with psychosis, delusional disorder and 
psychotic symptoms, combined with condition-specific 
(eg, aggression, agitation) and study type-specific (eg, 
random, RCT) terms. We plan no restrictions in terms of 
language, country or publication period for this search. 
We will also inspect similar systematic or non-systematic 
reviews as additional sources of potentially eligible trials. 
Search queries, dates and number of identified records 
will be published in the supplementary material and 
depicted in a PRISMA flowchart.
Studies selection
Two members of the team will independently review any 
identified record. In case of disagreement, the record will 
be included to assess its eligibility at the full-text phase. 
Two members of the team will independently review the 
full text of retrieved potentially eligible studies. We will 
develop a checklist of eligibility criteria to ease the system-
atic assessment of the retrieved full texts. We will resolve 
any disagreement by discussion with a third member of 
the team. Identified records referring to the same trial 
(ie, secondary publication) will be collated. We will clas-
sify trials according to the Cochrane Handbook defini-
tions in four mutually exclusive categories (ie, included, 
excluded, awaiting assessment, ongoing).41 We will list the 
reasons for exclusion and any other relevant comment 
in the supplementary material. We will contact original 
investigators of the trials to retrieve any additional infor-
mation deemed useful. In case of no response, we will send 
weekly reminders up to 3 weeks (ie, three reminders). We 
will report in the supplementary material any attempt 
to contact original investigators and the extent of their 
contribution (eg, information and/or data provided, no 
answer).
data extraction
We will design and use a structured data extraction form 
to ensure consistency of extracted information and data. 
We will extract the following data:
 ► Methods: date of the study, study design, randomi-
sation (ie, individual or cluster), number of study 
centres.
 ► Participants: number, proportion of first-episode 
patients, gender, age, underlying treatments, inclu-
sion and exclusion criteria, co-morbid disorders.
 ► Interventions: dose, dose range, dosing strategy, 
frequency of administration, route of administration, 
use of rescue medication.
 ► Outcomes: definition, measures, timing of assessment.
 ► Others: sponsorship or funding for trial (eg, industry, 
academic), notable conflict of interests of trial orig-
inal investigators.
Data estimates retrievable by graphs will be extracted 
(eg, mean, SD) using Plot Digitizer, an electronic ruler.42 
If both the SD and the SE are missing but p values or CIs 
are available, we will calculate SDs following the Cochrane 
Handbook guidelines.43 Should the original publication 
provide continuous data relevant to an outcome hereby 
specified as dichotomous, we will impute response rates 
from means and SD by employing a validated imputation 
method.44
Missing outcome data
To overcome the issue of missing outcome data, we aim at 
replicating the methods previously employed in a recent 
NMA on depression.45 For continuous outcomes, when 
data for a specific outcome is available for both inten-
tion-to-treat and per-protocol populations, preference 
will be given to the former. We will prefer data based on 
mixed-effect models of repeated measurements, multiple 
imputation or any other appropriate imputation methods 
over last-observation-carried-forward data.46 We will 
exclude participants with missing outcome data from the 
analysis. For the dichotomous efficacy outcome, we will 
assume that participants with missing outcome data failed 
to achieve an adequate response. Dropouts from assess-
ment will be assumed not to have changed from baseline 
for the given outcome: not in need of additional interven-
tions in terms of efficacy outcomes, and not having devel-
oped an adverse effect in terms of tolerability outcomes. 
We will evaluate the appropriateness of the imputation 
method in the Risk of bias judgement section.
Unit of analysis issues
We will extract data from cross-over studies only for the 
first phase (ie, before cross-over) to avoid including data 
potentially affected by the carry-over effect. However, 
given that we will extract data from relatively short trials, 
we expect cross-over effect to be unlikely. In trials that 
employ ‘cluster randomisation’ (eg, by practice or clini-
cian), we will extract data adjusted for the clustering 
effect. If these are not available, we will extract unad-
justed data and divide the sample size (for continuous 
outcomes) or both sample size and number of events (for 
dichotomous outcomes) by the design effect, defined as 
follows47:
 Design effect = 1 +
(
m− 1) ICC 
where m denotes the mean number of participants per 
cluster and ICC is the intra-cluster correlation coefficient, 
an estimate of the relative variability within and between 
clusters.48 If the ICC is not reported, we will assume it to 
be 0.1.49
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Comparability of dosages
Some trials may have employed unfair dose comparisons, 
possibly biasing the resulting estimate. To overcome this, 
we will add a dichotomous variable to indicate whether 
the comparison was fair by narrowing the eligible range 
of doses (ie, excluding lower and upper 20% of doses of 
the recommended or licensed ranges). Should a combi-
nation include two or more drugs at different levels of the 
range of doses, we will rate the combination according 
to the drug at the higher one (ie, hierarchically as upper 
range, mid-range, lower range).
risk of bias judgement
To evaluate the risk of bias, we will use the revised 
Cochrane risk of bias tool for randomised trials (RoB 2) 
(V.9, July 2019).50 Two independent raters will perform 
the evaluation following the full guidance document 
and using the provided Excel tool. In case of disagree-
ment, consensus will be reached either by discussion or 
by consultation of a third member of the team. Studies 
contributing to least one primary outcome will be 
assessed in the following domains: bias arising from the 
randomisation process, bias arising from identification 
or recruitment of individual participants within clusters 
(only for cluster-randomised trials), bias due to deviations 
from intended interventions (effect of assignment to the 
interventions at baseline), bias due to missing outcome 
data, bias in measurement of the outcome, bias in selec-
tion of the reported result.
Should a study contribute to both primary outcomes, 
we will provide two outcome-specific separate risk of bias 
judgements.
Additional domains
Additionally, we will evaluate the influence of sponsor-
ship and notable conflict of interest, defined as follow:
 ► Sponsorship (arm-level): (1) funded by a pharmaceu-
tical company with an active interest or (2) one or 
more authors were employees of such company.
 ► Notable conflict of interest (arm-level): (1) funded by 
a pharmaceutical company with an active interest, (2) 
one or more authors were employees of a company 
with an active interest, (3) having received speaker 
fees or honoraria from a company with an active 
interest or (4) having disclosed any other notable 
conflict of interest.
These two domains will not contribute towards the 
overall risk of bias judgement but will be separately 
addressed (refer to the Exploring heterogeneity, incon-
sistency and sensitivity analyses section).
Overall risk of bias judgement
Studies will be classified according to the guidance 
manual for RoB 250:
 ► Overall ‘low risk of bias’ if all the considered domains 
are rated to be at low risk of bias.
 ► Overall ‘some concerns’ if (1) at least one of the 
considered domains is rated to raise concern and (2) 
none of the considered domains is rated to be high 
risk of bias.
 ► Overall ‘high risk of bias’ if (1) at least one of the 
considered domains is rated to be at high risk of bias 
(irrespective of which domain is being assessed) or 
(2) the study is judged to raise concerns in multiple 
domains.
Statistical synthesis of study data
Characteristics of included studies and information flow in the 
network
We will provide descriptive statistics for the characteristics 
of trial and study population across eligible trials and also 
visualise relevant information by producing a network 
diagram. To understand which comparison contributes 
the most to the network estimate and how it affects the 
estimate, the percentage contribution of each direct 
meta-analysis will be described in a contribution matrix 
table.51
Pairwise meta-analyses
We will synthesise data of each pairwise comparison to 
obtain SMDs for continuous outcomes and ORs for 
dichotomous outcomes, and their 95% CIs. Assuming 
that different studies are measuring different but related 
treatment effects, we will use a random-effects model. We 
will compare the estimated distribution of the heteroge-
neity variance τ2 to predictive distributions, as described 
elsewhere.52 53
Assessment of the transitivity assumption
The transitivity assumption is the basic premise of a NMA. 
Distribution of clinical and methodological variables 
likely to act as effect modifiers will be investigated.54 55 We 
assume that individuals who fulfil the inclusion criteria 
are, in principal, equally likely to be randomised to any 
of the interventions of interest (ie, jointly randomisable). 
When additional evidence of intransitivity is lacking and 
potential effect modifiers have similar distribution across 
the included studies, NMA is likely to give valid results. 
We acknowledge that aggression and agitation might be 
conceived as different behavioural aspects. However, we 
will assume that individuals with psychotic symptoms and 
high levels of either aggression or agitation will have a 
similar clinical presentation and will receive similar inter-
ventions. Aggression or agitation due to psychotic symp-
toms induced by substance or medication use or due to a 
medical condition may moderate efficacy and tolerability 
of rapid tranquillisation interventions. For instance, anti-
psychotics are usually preferred over benzodiazepines 
in individuals with alcohol intoxication because of the 
risk of respiratory depression, while for other substances 
interventions other than antipsychotics are often prior-
itised to avoid increasing cardiotoxicity risk.56 Despite 
this, clinical presentation of these conditions in the acute 
setting may be difficult to distinguish. To overcome this, 
we restricted eligible studies to those focusing (ie, ≥50% 
of total recruited sample) on individuals with psychosis 
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not induced by external causes or medical conditions. We 
do not expect these last to be an effect modifier of effi-
cacy or tolerability of rapid tranquillisation interventions. 
Therefore, inclusion of diagnoses other than schizo-
phrenia should not threat the plausibility of our transi-
tivity assumption.
Other clinical or methodological variables that may 
influence our primary outcomes are year of study, age, 
baseline severity of aggression or agitation, baseline 
severity of mental state, comorbid substance or alcohol 
abuse (secondary diagnosis). We will investigate the 
distribution of these variables across studies grouped by 
comparison.
Network meta-analyses
If undertaking NMA is deemed appropriate as described 
above, we will perform a joint synthesis of all trials per 
outcome. Network diagrams for all the included studies 
and for the subsets contributing each outcome will be 
produced. For dichotomous outcomes of rare events, we 
will perform a common-effect Mantel-Haenszel NMA.57 
For all other outcomes, we will employ a random-effects 
NMA assuming a single heterogeneity parameter for all 
comparisons in each network. We will present summary 
estimates (ie, SMD, OR) for all pairwise comparisons in a 
league table. We will also provide the prediction intervals 
to assess how much the common heterogeneity affects the 
relative effect with respect to the additional uncertainty 
anticipated in a future study. We will calculate the prob-
ability for each drug to be ranked at each possible place 
and will present them in rankograms.58 To assess how 
likely it is for each drug to ‘beat’ most of its competitors 
in each outcome, we will calculate the SUCRA and the 
mean rank for each drug per outcome.58
Assessment of inconsistency
The statistical manifestation of transitivity is termed 
consistency, which relies on agreement between direct 
and indirect estimates.25 Since consistency can be assessed 
only in the presence of both direct and indirect evidence 
(ie, closed loop), when these are absent—by definition—
there cannot be inconsistency. Absence of statistical 
inconsistency never ensures the validity of transitivity, 
which itself remains an assumption.59 When closed loops 
are present in the network, inconsistency may result from 
variation of effect modifiers across treatment compari-
sons.60 To evaluate inconsistency, we will employ both local 
and global methods.54 59 We will employ the ‘separating 
indirect from direct evidence approach’, which separates 
direct evidence from indirect evidence to evaluate local 
consistency,59 61 and the design-by-treatment interaction 
test to evaluate consistency in the entire network.62 63
Exploring heterogeneity, inconsistency and sensitivity analyses
We expect small amounts of heterogeneity and incon-
sistency to be present. We will perform the following 
subgroup analyses for our two primary outcomes:
1. Sponsorship/notable conflict of interest.
2. Arms with a proportion equal to or greater than 50% 
of participants with comorbid substance-use disorders.
3. Route of administration. In case of combined treat-
ment with different routes of administration, we will 
classify it according to the drug at the higher level of 
range of doses (ie, hierarchically as upper range, mid-
range, lower range). Should it be the same, we will clas-
sify it as ‘intramuscular’.
We will also perform the following sensitivity analyses 
on the primary outcomes:
1. Blinding (ie, double-blind vs non double-blind).
2. Only studies with balanced dosages, by excluding arms 
with eligible but unfair dose comparison.
3. Only studies with an overall low risk of bias.
4. Contribution of combining drugs. If feasible, we will 
perform a component NMA assuming an additive con-
tribution of single drugs to drug combinations (ie, 
drug A and drug B to estimate the combination AB), 
and no interaction between the two. In this sensitivity 
analysis, we will group together all the benzodiazepine 
interventions both for single drugs and drug combi-
nations.
5. Administration of rescue drugs to evaluate the impact 
of including in the network studies in which rescue 
drugs were allowed but whose administration was not 
unbalanced.
6. Studies with specific inclusion criteria for agitation or 
aggression, by excluding studies with baseline mean 
levels suggesting the need for an intervention.
Selection bias
We will use comparison-adjusted and contour-enhanced 
funnel plots to explore whether results differ between 
imprecise and more precise trials.51 64
Model implementation
We will fit all models in R. We will use the meta package 
to perform pairwise meta-analyses.65 All the random-ef-
fects NMA will be fit using the netmeta package assuming 
a common τ2.66
Assessment of the confidence in the evidence from nMA
To assess the confidence we can place in the relative treat-
ment effects estimated in NMA, we will use the Confi-
dence in Network Meta-Analysis (CINeMA) framework, 
implemented in the web application https:// cinema. 
ispm. unibe. ch. CINeMA evaluates the credibility of the 
findings across the following domains: within-study bias, 
across-studies bias, indirectness, imprecision, heteroge-
neity and incoherence.67 68 Imprecision, heterogeneity 
and incoherence domains require to specify a clini-
cally important size of effect on the scale of the consid-
ered effect measure. We will set the following margin of 
non-equivalence: (1) active versus active comparison, a 
SMD of 0.1 for continuous outcome (severity of aggres-
sion/agitation) and an OR of 2.0 for dichotomous 
outcome (dropouts due to adverse events). We will apply 
these criteria to both active versus active and active versus 
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placebo comparisons, since we are mainly interested in 
relative effect of active treatments.
Patient and public involvement
No patient was involved in the protocol development nor 
will be involved in the review.
EthICS And dISSEMInAtIOn
This study does not require ethical approval. We will 
disseminate our findings by publishing results in a 
peer-reviewed journal.
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